Investigational drug · Phase 3
TG-C
Also called: TissueGene-C
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Degenerative Osteoarthritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
42
Any phase or sponsor naming "TG-C"
First trial start
2018
Oct 30, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TG-C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Degenerative Osteoarthritis
Approved drugs for the same conditions: Osteoarthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "TG-C" as an intervention, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00103285 · 5,377 participants · Start Apr 11, 2005 · Primary completion Dec 30, 2013
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 236 sites in all
- Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00075725 · 3,154 participants · Start Dec 29, 2003 · Primary completion Dec 31, 2010
Drug: Cyclophosphamide; Cytarabine and 10 more · For: Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 234 sites in all
- Combination Chemotherapy in Treating Children With Acute Lymphocytic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002812 · 2,078 participants · Start Sep 1996 · Primary completion Mar 2006
Drug: asparaginase; cyclophosphamide and 11 more · For: Leukemia
Sites: Long Beach, California; Los Angeles, California; Orange, California · 35 sites in all
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Associazione Italiana Ematologia Oncologia PediatricaAcademic, hospital or other
NCT00613457 · 2,039 participants · Start Sep 2000 · Primary completion Jul 2006
Drug: dexamethasone; asparaginase and 13 more · For: Leukemia
- Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002744 · 1,970 participants · Start May 1996 · Primary completion Mar 2007
Drug: asparaginase; cyclophosphamide and 11 more · For: Leukemia
Sites: Long Beach, California; Los Angeles, California; Orange, California · 34 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00408005 · 1,895 participants · Start Jan 30, 2007 · Primary completion Sep 30, 2017
Drug: Asparaginase; Cyclophosphamide and 12 more · For: T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 215 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A LiDAR-based reconstruction reveals increasing Arctic phytoplankton production during low-light winter-shoulder period.
Zhang Z, Chen P, Zhang S, et al. · Sci Adv 2026
- Seagrass sediment organic carbon burial rates are globally significant.
Arias-Ortiz A, Lafratta A, Colarusso P, et al. · Nat Commun 2026
- Dormant and green-up season mowing maximizes productivity-derived vegetation carbon input potential in coastal wetlands.
Wu J, Chu X, Li J, et al. · J Environ Manage 2026
- Dysphagia-friendly high internal phase emulsions stabilized by whey protein isolate-tamarind gum Maillard conjugates: rheological behavior, IDDSI compliance and stability.
Zhu P, Wang Z, Fan L, et al. · Food Res Int 2026
- Inland Migration Space Requirements for Maintaining Blue Carbon Stocks after Spartina Eradication under Accelerating Sea Level Rise.
Zhao W, Costa MDP, Lin S, et al. · Environ Sci Technol 2026
- Optimized Land-Water Management Expands Afforestation Potential Under Land and Human Water-Use Constraints.
Huang B, Lu F, Su Y, et al. · Adv Sci (Weinh) 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.